Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation

NAActive, not recruitingINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

September 3, 2021

Primary Completion Date

December 4, 2024

Study Completion Date

December 31, 2025

Conditions
Intracranial Aneurysm
Interventions
DEVICE

Endovascular treatment of unruptured aneurysms with p64 MW HPC Flow Modulation Device

Patients suffering from a distal intracranial aneurysm will be treated endovascularly with the p64 MW HPC Flow Modulation Device.

Trial Locations (18)

4051

Universitätsspital Basel, Basel

20133

Fondazione I.R.C.C.S. Instituto Neurologico Carlo Besta, Milan

33076

CHU Bordeaux, Bordeaux

34090

CHU de Montpellier, Montpellier

51092

CHU Reims - Hôpital Maison Blanche, Reims

69002

CHU de Lyon, Lyon

70174

Klinikum Stuttgart, Stuttgart

81377

Klinikum der LMU München, München

86156

Universitätsklinikum Augsburg, Augsburg

90471

Klinikum Nürnberg Süd, Nuremberg

94270

Hôpital Bicêtre, Le Kremlin-Bicêtre

99089

Helios Klinikum Erfurt, Erfurt

9112001

Hadassah University Medical Center, Jerusalem

06120

Universitätsklinikum Halle (Saale), Halle

Unknown

Klinikum Vest Recklinghausen, Recklinghausen

Western General Hospital, Edinburgh

04190

UNLP Košice, Košice

B15 2GW

Queen Elisabeth Hospital Birmingham, Birmingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Phenox GmbH

INDUSTRY

NCT04870047 - Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation | Biotech Hunter | Biotech Hunter